Faculty Advisor(s)

David Harris

Document Type


Publication Date



© 2022 Ashley McDonald


Neuromuscular blocking agents (NMBAs) are frequently utilized in anesthetic practice to relax the vocal cords in preparation for endotracheal intubation and to facilitate optimal operating conditions for various surgical procedures. Residual muscle paralysis in the postoperative period is a serious consequence of NMBAs that can lead to severe consequences including airway obstruction, hypoxia, reintubation, aspiration, and pneumonia. Neuromuscular blockade (NMB) is overcome either by spontaneous recovery or, in most cases, with the use of a reversal agent. Two of the most common reversal agents are neostigmine, a cholinesterase inhibitor, and sugammadex, a modified gamma-cyclodextrin. Of the two medications, sugammadex is a significantly more expensive option per dose, which creates budgetary concerns and leads to restrictions on its usage. However, sugammadex provides a markedly faster, more reliable, and more effective reversal of neuromuscular blockade compared to neostigmine with fewer side effects. By accelerating recovery from NMB with fewer adverse effects, patients spend less time in the operating room (OR) and post-anesthesia care unit (PACU) with fewer respiratory complications. Taking these factors into consideration, the higher medication cost of sugammadex can potentially be justified and/or offset by its superior safety profile and savings in OR and PACU time.


MSNA Capstone



To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.